Global Cancer Biomarkers Market 2015-2019, New Report Launched

Report forecast the Global Cancer Biomarkers market to grow at a CAGR of 18.26 percent over the period 2014-2019.

Biomarkers are molecules present in the blood, other body fluids such as serum, urine, or in tissue that are indicators of a disease or abnormal conditions. Biomarkers are mostly used as diagnostic tools. Biomarkers help in identifying potential drug failures in initial stages, leading to savings in time and costs. Biomarkers are becoming an essential part of the drug discovery process. Cancer Biomarkers are proteins or metabolites indicative of tumor state and progression characteristics. They are non-invasive, enable high speed cancer diagnosis and also enhance early cancer detection and screening.  The best example of a cancer biomarker is that of prostate specific antigen. PSA is measured in the blood to screen for and monitor treatment for prostate cancer. PSA, as a biomarker helps the doctors to monitor the progress of the cancer. It also helps to evaluate the response of the cancer to the treatment therapy.

Global Cancer Biomarkers Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Cancer Biomarkers market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

• Americas
• APAC
• EMEA       

Key Vendors

• Abbott Laboratories
• Affymetrix
• Illumina
• Qiagen 
• Quest Diagnostics
• Roche Diagnostics

Other Prominent Vendors

• Agendia
• Agilent Technologies
• Alere
• Ambry Genetics
• Amgen
• Astellas Pharma US
• Astex Pharmaceuticals
• Atossa Genetics
• Beckman Coulter
• Becton, Dickinson and Company
• Biocurex
• bioMérieux
• Celldex Therapeutics
• Clarient
• diaDexus
• DiagnoCure
• Epigenomics
• EUSA Pharma
• Exact Sciences
• Foundation Medicine
• Fujirebio Diagnostics
• Genomic Health
• Geron
• Immunomedics
• Morphotek
• Myriad Genetics
• Nodality
• Northwest Biotherapeutics
• Ocimum Biosolutions
• Oncothyreon
• OriGene
• Polymedco
• Radient Pharmaceuticals
• Randox Laboratories
• Siemens Healthcare
• US Biomarkers
• Vermillion

Market Driver

• Increased Prevalence of Cancer
• For a full, detailed list, view our report

Market Challenge

• Regulatory and Reimbursement Issues
• For a full, detailed list, view our report

Market Trend

• Growing Popularity of Companion Diagnostics
• For a full, detailed list, view our report

Key Questions Answered in this Report

• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Spanning over 89 pages, “Global Cancer Biomarkers Market 2015-2019” report covering the Executive Summary, List of Abbreviations, Scope of the Report, Market Research Methodology, Introduction, Market Landscape, Incidence and Prevalence, Biomarkers Used in Cancer Diagnosis, FDA Approval Process for Protein-Based Cancer Biomarkers, Geographical Segmentation, Buying Criteria, Market Growth Drivers, Drivers and their Impact, Market Challenges, Impact of Drivers and Challenges, Market Trends, Trends and their Impact, Vendor Landscape, Key Vendor Analysis. The report covered companies are - Abbott Laboratories,  Affymetrix,  Illumina,  Qiagen ,  Quest Diagnostics, Roche Diagnostics, Agendia,  Agilent Technologies, Alere, Ambry Genetics, Amgen, Astellas Pharma US,  Astex Pharmaceuticals, Atossa Genetics,  Beckman Coulter, Becton, Dickinson and Company,

Know more about this report at – http://mrr.cm/4Uu

Find all Diagnostics Reports at: http://www.marketresearchreports.com/diagnostics